Clinical Trial

A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Name: A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus — clinical trial record (NCT07405970)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-06

Trial Details

NCT Number	NCT07405970
Lead Sponsor	Beijing Mabworks Biotech Co., Ltd.
Conditions	Systemic Lupus Erythematosus
Enrollment	316 participants
Start Date	2026-04-10
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-05